Switzerland-based Carbogen Amcis announced a series of significant investments designed to enhancing its antibody drug conjugate (ADC) capabilities to better respond to increasing demand for ADCs in the development of highly targeted cancer treatments. The investments include a US$4 million clean room clinical supply facility at the Bubendorf, Switzerland site and a US $950,000 upgrade of the sterile manufacturing area at the facility in Riom, France. By adding on to the current High Potency facility, Carbogen Amcis is well positioned to offer its partners seamless development and manufacturing services for ADCs.
The upgrades at our Riom, France location include the implementation of a new vaporized hydrogen peroxide (VHP) disinfection system and the installation of two new aseptic filling isolators operating under nitrogen atmosphere and at regulated temperature, which will expand the Grade A (ISO 5) manufacturing capability at OELs below 1 µg/m3 8h-TWA, allowing a maximum batch size up to 5’000 units (2 mL vials).
